$549 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 83 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AZN | ASTRAZENECA PLCsponsored adr | $19,304,263 | -5.4% | 285,060 | 0.0% | 3.52% | +10.4% | |
| IMTX | IMMATICS N.V | $7,146,863 | +0.3% | 617,173 | 0.0% | 1.30% | +17.1% | |
| DAWN | DAY ONE BIOPHARMACEUTICALS I | $6,503,100 | +2.8% | 530,000 | 0.0% | 1.18% | +19.9% | |
| PNT | POINT BIOPHARMA GLOBAL INC | $6,354,122 | -26.4% | 952,642 | 0.0% | 1.16% | -14.2% | |
| NVS | NOVARTIS AGsponsored adr | $6,111,600 | +0.9% | 60,000 | 0.0% | 1.11% | +17.8% | |
| SRPT | SAREPTA THERAPEUTICS INC | $6,061,000 | +5.9% | 50,000 | 0.0% | 1.10% | +23.5% | |
| COGT | COGENT BIOSCIENCES INC | $4,095,000 | -17.7% | 420,000 | 0.0% | 0.75% | -3.9% | |
| XBI | SPDR SER TRs&p biotech | $3,651,000 | -12.2% | 50,000 | 0.0% | 0.66% | +2.3% | |
| GSK PLCsponsored adr | $3,625,000 | +1.7% | 100,000 | 0.0% | 0.66% | +18.7% | ||
| GILD | GILEAD SCIENCES INC | $2,997,600 | -2.8% | 40,000 | 0.0% | 0.55% | +13.5% | |
| MORF | MORPHIC HLDG INC | $2,061,900 | -60.0% | 90,000 | 0.0% | 0.38% | -53.3% | |
| VERA | VERA THERAPEUTICS INCcl a | $1,439,550 | -14.6% | 105,000 | 0.0% | 0.26% | -0.4% | |
| HOWL | WEREWOLF THERAPEUTICS INC | $1,341,373 | -29.8% | 626,810 | 0.0% | 0.24% | -18.4% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $1,326,376 | -16.3% | 1,228,126 | 0.0% | 0.24% | -2.0% | |
| QURE | UNIQURE NV | $998,005 | -41.4% | 148,734 | 0.0% | 0.18% | -31.6% | |
| ELEV | ELEVATION ONCOLOGY INC | $596,340 | -56.4% | 900,000 | 0.0% | 0.11% | -49.1% | |
| IMTXW | IMMATICS N.V*w exp 07/01/202 | $354,000 | +3.5% | 100,000 | 0.0% | 0.06% | +20.8% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.